Findings from a phase I study suggest that the durability of patients' response to CAR T-cell therapy, and their long-term survival, are influenced by whether they have minimal residual or morphologic disease prior to treatment. The former fared better overall, and also experienced less-severe side effects from this form of immunotherapy.
from Cancer via ola Kala on Inoreader http://ift.tt/2qMNllp
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου